Genetic Technologies (AU:GTG)
ASX:GTG
Top Page
Genetic Technologies
(Sydney:GTG)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.04
▼(-5.00% Downside)
Action:N/ADate:07/19/25
The overall stock score of 44 for AU:GTG is primarily driven by weak financial performance, with declining revenue, significant losses, and negative cash flow highlighting operational and sustainability risks. Valuation concerns due to negative P/E and lack of dividends further weigh on the score, while neutral technical indicators provide no strong counterbalance.
Genetic Technologies (GTG) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.67M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)2.20
Revenue Growth-56.35%
EPS Growth42.80%
CountryAU
Employees55
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,335,422,500
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)5.85
Price to Sales (P/S)1.40
P/FCF Ratio-1.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genetic Technologies Business Overview & Revenue Model
Company Description
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, an...
How the Company Makes Money
Genetic Technologies makes money through the sale of its genetic testing products and services. The company's primary revenue stream comes from the commercialization of its proprietary genetic risk assessment tests, which are sold directly to heal...
Genetic Technologies Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
35
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.21M | 7.66M | 10.35M | 6.79M | 120.55K | 837.87K |
| Gross Profit | 3.21M | 3.90M | 6.01M | 6.47M | -240.47K | 736.43K |
| EBITDA | -6.64M | -11.43M | -11.20M | -7.20M | -6.58M | -5.87M |
| Net Income | -9.68M | -12.02M | -11.75M | -7.13M | -7.08M | -6.29M |
Balance Sheet | ||||||
| Total Assets | 1.75M | 6.19M | 14.86M | 20.80M | 22.97M | 15.63M |
| Cash, Cash Equivalents and Short-Term Investments | 1.01M | 1.02M | 7.87M | 11.73M | 20.90M | 14.22M |
| Total Debt | 500.00K | 875.19K | 532.85K | 652.53K | 204.04K | 481.79K |
| Total Liabilities | 3.92M | 4.36M | 3.69M | 4.37M | 1.44M | 1.64M |
| Stockholders Equity | -2.17M | 1.83M | 11.16M | 16.43M | 21.53M | 13.99M |
Cash Flow | ||||||
| Free Cash Flow | -5.75M | -9.71M | -9.74M | -5.76M | -6.94M | -5.75M |
| Operating Cash Flow | -5.74M | -9.68M | -9.72M | -5.66M | -6.30M | -5.71M |
| Investing Cash Flow | 431.55K | 114.90K | -311.94K | -3.49M | -642.00K | 64.79K |
| Financing Cash Flow | 2.73M | 2.82M | 5.92M | -279.06K | 13.94M | 18.36M |
Genetic Technologies Technical Analysis
Positive
0.04
Price Trends
0.04
Positive
0.04
Negative
0.04
Positive
Market Momentum
>-0.01
Neutral
100.00
Negative
0.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GTG, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:GTG.
Genetic Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$64.67M | -4.75 | -476.27% | ― | ― | 56.42% | |
49 Neutral | AU$42.02M | -1.06 | -63.04% | ― | 29.60% | 33.00% | |
46 Neutral | AU$168.57M | -7.39 | -164.12% | ― | 12.96% | 40.81% | |
44 Neutral | AU$5.67M | -0.55 | -184.98% | ― | -56.35% | 42.80% | |
42 Neutral | AU$33.18M | -2.45 | -164.22% | ― | ― | 23.85% | |
41 Neutral | AU$18.17M | -2.23 | -23.93% | ― | 62.81% | 16.37% |
* Healthcare Sector Average
AU:GTG
Genetic Technologies
0.04
0.00
0.00%
AU:BDX
BCAL Diagnostics Limited
0.09
-0.01
-10.00%
AU:RHY
Rhythm Biosciences Ltd.
0.19
0.12
171.43%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.21
0.19
950.00%
AU:GSS
Genetic Signatures Ltd.
0.08
-0.32
-80.00%
AU:MAP
Microba Life Sciences Limited
0.07
-0.11
-61.67%
Genetic Technologies Corporate Events
Genetic Technologies Director Anthony Hartman Steps Down
Dec 19, 2025
Genetic Technologies Limited has announced that director Anthony Hartman has ceased to be a director of the company as of 9 September 2025. The filing with the ASX indicates that Hartman holds no relevant interests in the company’s securitie...
Genetic Technologies Appoints New Director, Discloses Major Indirect Shareholding
Dec 19, 2025
Genetic Technologies Limited has notified the ASX that Steven Nicols has been appointed as a director of the company effective 19 December 2025, in accordance with listing rule 3.19A.1 and relevant Corporations Act provisions. The filing discloses...
Genetic Technologies Reshapes Board and Tightens Governance Ahead of Relisting
Dec 19, 2025
Genetic Technologies has announced the resignation of director Anthony Hartman, effective 9 September 2025, and the appointment of experienced ASX-listed company director Steve Nicols as a non-executive director from 19 December 2025, bolstering t...
Genetic Technologies Announces Change in Company Secretary
Dec 2, 2025
Genetic Technologies Limited announced the resignation of Mr. Mark Ziirsen as the Joint Company Secretary, effective December 1, 2025. Ms. Priyamvada (Pia) Rasal will continue as the sole Company Secretary, handling communications between the comp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.